Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
100.00    -3.20 (-3.10%)
Bid:
100.00
Ask:
102.20
Spread: 2.20 (2.20%)
Market Cap: £163.94m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Trading Update

15 May 2008 07:00

RNS Number : 4877U
Yule Catto & Co PLC
15 May 2008
 



Yule Catto & Co plc 

AGM Statement and Trading Update

At today's Annual General Meeting of Yule Catto & Co plc to be held at 12.00 noon at Saddlers' Hall, 40 Gutter Lane, London EC2V 6BR, Anthony Richmond-Watson, Chairman, will make the following statement, which comprises Yule Catto's Interim Management Statement for the period from 1 January 2008 to date.

"2007 was a good year for the Group. We made steady progress across all of our divisions in both our operational performance and strategic plans to develop the Group for the future. This showed through in the financial results.

"The Polymers business had another good year of growth in volumes and profit. Our strategy in Polymers remains focused on geographical expansion around our existing business hubs and developing market sectors where our product technology and manufacturing capabilities give us real competitive advantage. We are investing heavily in additional Nitrile capacity in Malaysia to take full advantage of the continued growth in this product and the Asian region.

"Our Pharma business continued to grow the range of generic and ethical products that it plans to manufacture by registering further drug master files in the year. As we had previously indicated Pharma earnings declined, in part due to the phasing of orders in the second half of the year. We announced plans to exit our Italian site to improve the operational cost base and the productivity of the business. This exit is proceeding to plan.

"Impact Chemicals has had a challenging year, but has delivered significant improvement. We are clearly seeing the benefits of our strategy to raise the performance of these businesses through restructuring and focussing on market segments offering better margins and growth.

"Overall, underlying Group profit before taxation increased some 10% to £34.5 million, and earnings per share by 18% to 17.3 pence per share.

"This has been a year in which much has been achieved. On behalf of the directors and shareholders, I would like to thank all our employees everywhere for their commitment and contribution towards the company's success.

Management Changes

"Alan Maddy, Chief Executive of the Polymer Division, will be retiring in August this year after 38 years with the Group. He is replaced by Derick Whyte, who was previously CEO of the Impact Division. Adrian Whitfield has assumed direct management control of the Impact businesses.

Board Changes

"David Blackwood joined the Group and the Board as Finance Director in October last year. Sandy Dobbie and Jez Maiden were appointed independent non-executive directors in August; their appointments arise out of our regular review of the board's composition. In the coming year we expect to address such issues further.

As far as my position as Chairman is concerned, I have decided that now is an appropriate time for the Board to initiate a process to appoint my successor.

"Messrs. Blackwood, Dobbie and Maiden seek election today having been appointed since the 2007 AGM. Dato' Seri Lee Oi Hian, Dato' Lee Hau Hian, Alex Catto and myself are also standing for re-election at today's meeting

Interim Management Statement

"2008 has started positively, with our un-audited management accounts showing revenues and profits in-line with our expectations and ahead of last year.

"Polymer Chemicals made solid start to the year, ahead on sales and profit, supported by the expanded nitrile capacity in Malaysia, where we remain on track to further expand nitrile capacity by approximately 60during the second half of the year.

"Pharma Chemicals experienced a very strong first half in 2007 based in the main on customer order phasing. Profit for the first quarter of this year is consequently below last year, but the results are in line with our expectations.

"The results for Impact Chemicals are ahead of last year as expected, benefitting from the restructuring programme. We have implemented further restructuring at William Blythe in the first quarter, and results there should further improve through the rest of the year.

"Overall the year has started well, though we see general signs of economic weakness around the world. We remain focused on delivering value from the Impact portfolio and improving the Pharma business through the Italian site restructuring programme. The Polymers business has made a solid start to the year, and should show further improvement again this year. Overall, despite the economic concerns we remain confident that 2008 will be a year of further improvement for the Group." 

15 May 2008

ENQUIRIES:

YULE CATTO 

Tel: 01279 442791

Adrian Whitfield, Chief Executive 

David Blackwood, Finance Director 

 

COLLEGE HILL 

Tel: 020 7457 2020 

Gareth David

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTAIMFTMMABBIP
Date   Source Headline
29th Sep 20227:00 amRNSTrading update
23rd Sep 20229:23 amRNSHolding(s) in Company
12th Sep 20223:27 pmRNSHolding(s) in Company
6th Sep 20228:15 amRNSHolding(s) in Company
12th Aug 20229:22 amRNSDirector/PDMR Shareholding
11th Aug 20227:00 amRNSDirector/PDMR Shareholding
9th Aug 20224:09 pmRNSHolding(s) in Company
9th Aug 20227:00 amRNSDirector/PDMR Shareholding
5th Aug 20221:20 pmRNSHolding(s) in Company
5th Aug 202211:27 amRNSDirector/PDMR Shareholding
4th Aug 20222:57 pmRNSDirector/PDMR Shareholding
4th Aug 20222:35 pmRNSDirector/PDMR Shareholding
3rd Aug 202212:29 pmRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSResults for the six months ended 30 June 2022
15th Jul 20222:32 pmRNSHolding(s) in Company
8th Jul 202210:23 amRNSHolding(s) in Company
1st Jul 20227:00 amRNSChief Financial Officer
30th Jun 20225:04 pmRNSHolding(s) in Company
21st Jun 20227:00 amRNSAppointment of Non-Executive Director
17th May 202212:55 pmRNSHolding(s) in Company
5th May 202212:39 pmRNSHolding(s) in Company
4th May 20224:46 pmRNSDirector/PDMR Shareholding
4th May 20227:00 amRNSAppointment of Joint Corporate Brokers
28th Apr 202212:24 pmRNSResult of AGM
28th Apr 20227:00 amRNSQ1 2022 trading update
26th Apr 20229:33 amRNSHolding(s) in Company
20th Apr 20224:13 pmRNSHolding(s) in Company
5th Apr 20224:18 pmRNSDirector/PDMR Shareholding
1st Apr 20221:34 pmRNSCompletion of adhesives acquisition
29th Mar 20223:17 pmRNSHolding(s) in Company
29th Mar 20223:14 pmRNSDirector/PDMR Shareholding
25th Mar 20222:03 pmRNSAnnual Financial Report
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:48 pmRNSDirector/PDMR Shareholding
14th Mar 20229:35 amRNSHolding(s) in Company
9th Mar 202212:52 pmRNSDirector/PDMR Shareholding
8th Mar 20223:22 pmRNSDirector/PDMR Shareholding
8th Mar 20223:19 pmRNSDirector/PDMR Shareholding
3rd Mar 20227:00 amRNSPreliminary Results for the year ended 31 Dec 2021
14th Feb 20227:00 amRNSPre-close trading update
10th Feb 20223:10 pmRNSNOTIFICATION OF MAJOR HOLDINGS
22nd Dec 20215:10 pmRNSDirector/PDMR Shareholding
21st Dec 20213:09 pmRNSDirector/PDMR Shareholding
20th Dec 20213:40 pmRNSDirector/PDMR Shareholding
17th Dec 202112:29 pmRNSResults of General Meeting
15th Dec 20212:54 pmRNSDirector/PDMR Shareholding
30th Nov 20214:57 pmRNSPUBLICATION OF CIRCULAR
26th Nov 20217:00 amRNSAppointment of Chief Financial Officer
22nd Nov 202110:36 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.